Research Analysts Issue Forecasts for LXRX FY2027 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at HC Wainwright issued their FY2027 earnings estimates for Lexicon Pharmaceuticals in a research report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($0.21) for the year. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2028 earnings at ($0.18) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $3.14 million.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.63.

Lexicon Pharmaceuticals Price Performance

Shares of Lexicon Pharmaceuticals stock opened at $1.64 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The business has a 50 day simple moving average of $1.35 and a two-hundred day simple moving average of $1.33. The stock has a market capitalization of $596.09 million, a P/E ratio of -8.63 and a beta of 0.94. Lexicon Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $1.83.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Hudson Bay Capital Management LP purchased a new stake in Lexicon Pharmaceuticals in the 2nd quarter valued at about $26,000. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $31,000. Leonteq Securities AG acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $34,000. EntryPoint Capital LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $39,000. Finally, Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at approximately $42,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lexicon Pharmaceuticals

In other news, Director Raymond Debbane bought 100,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the acquisition, the director directly owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. This trade represents a 5.54% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Invus Global Management, Llc purchased 1,538,462 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were purchased at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares in the company, valued at approximately $2,000,000.60. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 1,790,462 shares of company stock worth $2,369,981 over the last ninety days. 13.90% of the stock is owned by insiders.

Trending Headlines about Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $6.00 and reiterated a Buy, signaling strong analyst conviction and large implied upside versus the current price. Higher analyst targets can attract buyers and support momentum. Street Insider: PT Raised to $6
• Positive Sentiment: Q4 results beat estimates: GAAP EPS of -$0.04 beat consensus and revenue of $5.49M topped forecasts, which reduces near?term execution risk and supports the narrative of improving fundamentals. Earnings Beat
• Positive Sentiment: Clinical and corporate milestones announced: planned NDA resubmission for sotagliflozin in T1D, SONATA enrollment for HCM, positive End?of?Phase?2 meeting for pilavapadin (supporting Phase 3 readiness), and ongoing partnership talks — all de?risk future value catalysts. Press Release: Q4 Results & Clinical Updates
• Positive Sentiment: Balance sheet strengthened: management disclosed more than $100M in additional cash from a capital raise and a Novo Nordisk milestone payment, improving runway and reducing near?term financing risk. Press Release: Cash Update
• Neutral Sentiment: Management commentary and full Q4 call transcript available for investors to assess execution details and timelines. Review the transcript/webcast for guidance nuances. Earnings Call Transcript
• Neutral Sentiment: Analyst model updates: HC Wainwright published FY2027/FY2028 EPS forecasts (-$0.21 and -$0.18) that are better than the current consensus (-$0.66 for the year), reflecting expectations of narrowing losses but still negative near?term earnings. Analyst Estimates
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative ROE; earnings are expected to remain below zero in the near term—a structural risk that keeps the stock speculative. Earnings Detail

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.